Navigation Links
Scottish Scientists Test ‘Secret Weapon’ Against,Tumours

LONDON, March 8, 2007--Cancer Research UK scientists in Glasgow have devised a new method of attacking cancer cells. They report the findings in the Journal of Clinical Investigation* today (Thursday).

A team of scientists from the Beatson Institute for Cancer Research gave mice a chemical that caused cancer cells to commit suicide, significantly slowing the growth of the tumours they were carrying. The chemical kick started a gene called p73 that brings about cancer cell death.

This early research could pave the way for a new agent to stop tumours growing. The researchers suggest that sending the protein – called 37AA – directly into the bloodstream using a ‘nanoparticle’ delivery system could be a potential way to find and kill tumour cells that have spread as well as those in the primary tumour.

In further laboratory studies the research team found that the chemical could kill several types of cancer cells – including bowel, cervical and bone cells.

Lead researcher Dr Kevin Ryan, a Cancer Research UK senior research fellow and head of the Tumour Cell Death Laboratory at the Beatson Institute, said: “Our study has shown for the first time that the selective activation of a gene called p73 can cause cell death in tumours. We think this approach has the potential to be developed into an effective treatment for cancer.”

The gene p73 is related to p53 – one of the most important genes known to protect against the development of cancer. p53, known as the ‘guardian of the genome’, was first identified by Cancer Research UK scientists in London.

p53 is damaged in the vast majority of cancers so scientists across the globe are looking for ways to restore the gene as a way of treating the disease. However, in some cancers, p53 is damaged in such a way that its function cannot be restored. p73 is a promising alternativ e target because it is rarely defective in human cancers.

Dr Ryan added: “Previously we thought p73 was just a ‘sleeping partner’ of p53, so we’re really excited that we’ve found a way to harness its function to treat cancer. While our studies are still at a preliminary stage, the next phase of our work is going to focus on developing a drug that mimics the effect of the 37AA protein. We hope this strategy could then be more readily tested for its potential development in human tumours.”

Professor Jim Cassidy, Cancer Research UK’s chair of medical oncology in Scotland said: “This fascinating piece of basic research has resulted in an experimental treatment that can cause malignant tumours to stop growing. In laboratory tests it killed a range of different cancer cells. We look forward to seeing if switching on p73 can translate into a treatment for patients.”

For media enquiries, please contact Emma Gilgunn-Jones in the press office on 020 7061 8311, or, out of hours, the duty press officer on 07050 264 059.

Notes to Editors:

*A novel p53-derived apoptotic peptide de-represses p73 to cause tumor regression in vivo. Helen S. Bell et al, 2007. Journal of Clinical Investigation.

This research was funded by Cancer Research UK with support from the Biotechnology and Biological Sciences Research Council (BBSRC) and the Ludwig Institute for Cancer Research.

Cancer Research UK - Together with its partners and supporters, Cancer Research UK's vision is to beat cancer. - Cancer Research UK carries out world-class research to improve understanding of the disease and find out how to prevent, diagnose and treat different kinds of cancer. - Cancer Research UK ensures that its findings are used to improve the lives of all cancer patients. - Cancer Research UK helps people to understand cancer, the progress that is being made and the choices each person can make.

- C ancer Research UK works in partnership with others to achieve the greatest impact in the global fight against cancer.

For further information about Cancer Research UK's work or to find out how to support the charity, please call 020 7009 8820 or visit www.cancerresearchuk.org.uk.


'"/>




Related medicine technology :

1. Rosetta Genomics and Weizmann Institute Scientists Identify Role of microRNA in Cancer Suppression
2. Schepens Scientists Identify Key to Integrating Transplanted Nerve Cells Into Injured Tissue
3. Karmanos Physician-Scientists Examine Racial Disparities in Patients with Gynecologic Cancer
4. Scientists Implicate Gene in Vitiligo and Other Autoimmune Diseases
5. The Sturdier Sex?: Study by Pittsburgh Scientists Finds Female Stem Cells Work Better
6. Alnylam and Stanford University Scientists Discover New Role for microRNAs (miRNAs) in T Cell Biology and Immunity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... , First quarter 2016 adjusted diluted earnings per share ... , First quarter reported diluted (GAAP) loss per share ... revises 2016 financial guidance; now expects 2016 revenues to range ... non-GAAP earnings per share to range from $4.50 to $4.80 ... and manufacturing facility restructuring , Company expands ...
(Date:5/5/2016)... Calif. , May 5, 2016  Diagnostic ... a decade due to concerns that these tests ... the approach to imaging, as well as the ... new era of medical peripherals that help health care providers ...   Ampronix  advanced medical imaging is a renowned authorized ...
(Date:5/5/2016)... DUBLIN , May 5, 2016 ... for PET Imaging in Top 5 EU Markets"  report to ... This report provides information on the current Positron Emission ... Five European Markets (T5 EU), which includes France ... , Spain and the ...
Breaking Medicine Technology:
(Date:5/6/2016)... ... May 06, 2016 , ... The National Association of Chain ... in Puerto Rico. Radio messages set to debut on Monday, May 9, and ... about ways to protect themselves and their unborn children from the effects of ...
(Date:5/6/2016)... ... May 06, 2016 , ... DrugDev President ... the way the pharmaceutical industry conducts clinical trials. This month Ibs was named No. ... in pharma, and he was honored as a Tech Disruptor by the Philadelphia Business ...
(Date:5/6/2016)... , ... May 06, 2016 , ... ... Integration Service, their latest implementation service offering for global clients of Coupa ( ... ). , Bluvault’s Integration Service is a key component in the suite ...
(Date:5/6/2016)... ... May 06, 2016 , ... From May 4 to 6, EarQ ... the unique opportunity to learn more about Signia’s technology and the successful business and ... is our priority to see practices succeed in this highly competitive industry,” said Ed ...
(Date:5/6/2016)... ... May 06, 2016 , ... Multiple award winning plumbing company in ... 35 years. Maintaining core values of exceptional customer service, quality work at reasonable rates, ... leading name in San Diego plumbing, and other services including heating & air conditioning ...
Breaking Medicine News(10 mins):